Unlike most reference studies, which assessed hepcidin levels in breast cancer patients a year and a half or more after treatment to compare relapsing and non‐relapsing patients‐demonstrating elevated hepcidin levels in those who recurrence, This study measured hepcidin levels at diagnosis, before any treatment was initiated, to predict which patients might recurrence based on hepcidin values. This evidence concerns the gene HAMP and breast carcinoma.